Prophylactic Anticoagulant Treatment Might Have an Anti-inflammatory Effect and Reduce Mortality Rates in Hospitalized COVID-19 Patients?

Basit Öğe Kaydı
dc.contributor.authorAlkan, Sevil
dc.contributor.authorŞener, Alper
dc.contributor.authorDoğan, Ebru
dc.contributor.authorYüksel, Cihan
dc.contributor.authorYüksel, Buse
dc.date.accessioned2025-01-27T19:00:46Z
dc.date.available2025-01-27T19:00:46Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjectives: COVID-19 associated coagulopathy and prophylactic anticoagulant therapy (PAT) are ongoing topics globally. Using PAT for anti-inflammatory effect may prevent thromboembolic events (TEEs). The objective of this study was to determine the anti-inflammatory effects of PAT in hospitalized COVID-19 patients. Methods: We conducted a retrospective observational study in a tertiary pandemic hospital. Patients were divided into two categories according to their PAT therapy status (PAT (+) and PAT (-)) and into three categories according to clinical features (mild: group 1; moderate: group: 2; and severe: group 3). We then evaluated laboratory parameters and clinical courses. Results: We included 662 hospitalized COVID-19 patients in this study. Enoxaparin sodium was given to all patients as PAT therapy. TEE was developed in five patients in the PAT (+) group. Pulmonary embolism developed in 3/5 patients and deep venous thrombosis in 2/5 patients. Disseminated intravascular coagulation (DIC) was detected in 54 patients in group 3. No statistically significant difference was found in 28-day mortality, development of DIC rates, intubation rates, and TEEs. Conclusions: The use of PAT in critically ill patients was not effective in reducing C-reactive protein, which is one of the biomarkers of inflammation. © 2022, Oman Medical Specialty Board. All rights reserved.
dc.identifier.doi10.5001/omj.2022.77
dc.identifier.issn1999-768X
dc.identifier.issue4
dc.identifier.scopus2-s2.0-85133525604
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.5001/omj.2022.77
dc.identifier.urihttps://hdl.handle.net/20.500.12428/13457
dc.identifier.volume37
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherOman Medical Specialty Board
dc.relation.ispartofOman Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20250125
dc.subjectAnti-Inflammatory Agents; Anticoagulants; COVID-19
dc.titleProphylactic Anticoagulant Treatment Might Have an Anti-inflammatory Effect and Reduce Mortality Rates in Hospitalized COVID-19 Patients?
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu